The Quantellect read.As of Nov 19, 2026, 9 active firms cover SAB Biotherapeutics Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.29 sits 285% above the current $3.19. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.29
+285.1% upside
Average target across 7 active firms as of Nov 19, 2026 vs $3.19 current
Highest Target$16.00
Average Target$12.29
Lowest Target$10.00
Detailed analyst forecasts for SABS
Showing 1–7 of 7 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate SABS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SABS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.32 – $-0.21 · 3 analysts
Next period, 3 analysts expect SAB Biotherapeutics Inc to earn $-0.25 a share (range $-0.32 – $-0.21), versus — a year earlier. Full-year consensus is $-1.13, growing to $-0.94 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $62.5K next year.
Top analysts covering SAB Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SABS.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$15.00+370.2% to target
Overall win rate
50%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$11.00+244.8% to target
Overall win rate
43%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Buy
$16.00+401.6% to target
Overall win rate
41%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$11.00+244.8% to target
Overall win rate
41%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #404
Buy
$14.00+338.9% to target
Overall win rate
35%
+ Follow
SABS stock forecast FAQ
What is SABS's average 12-month price target?+
The 7 active firms with a live target average $12.29 for SAB Biotherapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low, as of Nov 19, 2026.
Is SABS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SABS?+
The Street-high target is $16.00 (Chardan Capital), and the Street-low is $10.00 (HC Wainwright & Co.). The average of all 7 active-firm targets is $12.29.
How many active Wall Street firms cover SABS?+
9 active firms have a recognized rating on SAB Biotherapeutics Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SABS?+
Among analysts who currently cover SABS, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $15.00 target.
What is SAB Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.32 – $-0.21) across 3 analysts. Full-year EPS is projected at $-1.13, rising to $-0.94 the following year.
How much revenue is SAB Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $62.5K next year.
Have analysts been upgrading or downgrading SABS lately?+
As of Nov 19, 2026, 9 of 9 active firms rate SABS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SABS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.